{'fraction_non_alphanumeric': 0.02142051860202931, 'fraction_numerical': 0.02367531003382187, 'mean_word_length': 6.219512195121951, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Derived Postbiotics of a Multi‐strain Probiotic Formula Clinically Validated for the Treatment of Irritable Bowel Syndrome

The pathophysiology of Irritable Bowel Syndrome (IBS) involves increased intestinal permeability, micro‐inflammation and gut dysbiosis with associated visceral hypersensitivity. The probiotic mix of Lactobacillus plantarum strains CECT7484 (KABP022) and CECT7485 (KABP023) and Pediococcus acidilactici CECT7483 (KABP021) has shown positive clinical outcomes in IBS. However, their exact mechanisms of action have not been elucidated. Postbiotics are probiotic‐derived metabolites or cell components that can improve host health. In this work we sought to characterize said strains about the production of specific postbiotics known to influence gut permeability and inflammation, as well as their inhibitory activity against bacteria known to be increased in IBS.